---
title: "ZYPEEK: Chief Financial Officer Yang Liping plans to reduce holdings of no more than 30,000 shares of the company"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/257529847.md"
description: "On the evening of September 16, ZYPEEK announced that the company's director and CFO Yang Liping plans to reduce her holdings of the company's shares by no more than 30,000 shares, or no more than 0.0247% of the company's total share capital, within three months after 15 trading days from the date of the announcement due to personal funding needs. The reduction price will be determined based on the market price at the time of the reduction"
datetime: "2025-09-16T11:11:32.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/257529847.md)
  - [en](https://longbridge.com/en/news/257529847.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/257529847.md)
---

# ZYPEEK: Chief Financial Officer Yang Liping plans to reduce holdings of no more than 30,000 shares of the company

On the evening of September 16, ZYPEEK announced that the company's director and CFO Yang Liping plans to reduce her holdings of the company's shares by no more than 30,000 shares, or no more than 0.0247% of the company's total share capital, within three months after 15 trading days from the date of the announcement due to personal funding needs. The reduction price will be determined based on the market price at the time of the reduction

### Related Stocks

- [688716.CN](https://longbridge.com/en/quote/688716.CN.md)

## Related News & Research

- [Best of BS Opinion: FTA strains, virus alerts, and market reform debate](https://longbridge.com/en/news/286835751.md)
- [Europe-China spacecraft launches to study Earth's 'invisible armour'](https://longbridge.com/en/news/286881963.md)
- [Marvel Biosciences Announces Grant of Deferred Share Units | MBCOF Stock News](https://longbridge.com/en/news/287056256.md)
- [Apple Flavor to Buy NovoSana’s China Assets for Up to USD66 Million in Health Supplements Push](https://longbridge.com/en/news/287039106.md)
- [20:00 ETAccro Bioscience Announces $50 Million Series C Financing Led by OrbiMed to Advance Clinical Pipeline for Immune Mediated Diseases](https://longbridge.com/en/news/286830151.md)